1489103-07-2

Upstream product

• 684238-90-2 9-[(2-hydroxyethyl)amino]-1,2,3,4-tetrahydroacridine 
• 191936-15-9 7-(3-bromopropoxy)-2-(p-tolyl)-4H-chromen-4-one 
• 1489102-49-9 N-(3-(piperazin-1-yl)propyl)-1,2,3,4-tetrahydroacridin-9-amine 
• 108-94-1 cyclohexanone 
• 5396-30-5 9-chloro-1,2,3,4-tetrahydroacridine 
• 118-92-3 anthranilic acid 
• 78298-69-8 4'-Methyl-7-hydroxyflavone 
• 874-60-2 4-methyl-benzoyl chloride 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 

Relevant academic research and scientific papers

Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease

A new series of tacrine-flavonoid hybrids (13a-u) had been designed, synthesized, and evaluated as multifunctional cholinesterase (ChE) inhibitors against Alzheimer's disease (AD). In vitro studies showed that most of the molecules exhibited a significant ability to inhibit ChE and self-induced amyloid-β (Aβ1-42) aggregation. Kinetic and molecular modeling studies also indicated compounds were mixed-type inhibitors, binding simultaneously to active, peripheral and mid-gorge sites of AChE. Particularly, compound 13k was found to be highly potent and showed a balanced inhibitory profile against ChE and self-induced Aβ1-42 aggregation. Moreover, it also showed excellent metal chelating property and low cell toxicity. These results suggested that 13k might be an excellent multifunctional agent for AD treatment.